Clinical trialNCT06616584RecruitingPhase 2, PHASE3Interventional

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SponsorSWOG Cancer Research NetworkEnrollment378Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Saiama N Waqar
SWOG Cancer Research Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

386 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Gulf Health Hospitals Inc/infirmary Cancer Care - Malbis
Daphne, Alabama, United States
Jan O. Kemnade
Recruiting
Thomas Hospital
Fairhope, Alabama, United States
Jan O. Kemnade
Recruiting
Mobile Infirmary Medical Center
Mobile, Alabama, United States
Jan O. Kemnade
Recruiting
Gulf Health Hospitals Inc/infirmary Cancer Care - Saraland
Saraland, Alabama, United States
Jan O. Kemnade
Recruiting
Katmai Oncology Group
Anchorage, Alaska, United States
Charles W. Drescher
Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona, United States
Linda L. Garland
Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
Linda L. Garland
Recruiting
Nea Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, United States
Wail Alnas
Recruiting
Kaiser Permanente-Anaheim
Anaheim, California, United States
Eric C. McGary
Recruiting
Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States
Eric C. McGary
Recruiting
Kaiser Permanente-Bellflower
Bellflower, California, United States
Eric C. McGary
Recruiting
Tower Cancer Research Foundation
Beverly Hills, California, United States
Karen L. Reckamp
Recruiting
Enloe Medical Center
Chico, California, United States
Tianhong Li
Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Tanyanika L. Phillips
Recruiting
Kaiser Permanente-Fontana
Fontana, California, United States
Eric C. McGary
Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California, United States
Jennifer M. Suga
Recruiting
Kaiser Permanente-Fresno
Fresno, California, United States
Jennifer M. Suga
Recruiting
Kaiser Permanente South Bay
Harbor City, California, United States
Eric C. McGary
Recruiting
City of Hope at Irvine Lennar
Irvine, California, United States
Tanyanika L. Phillips
Recruiting
Kaiser Permanente-Irvine
Irvine, California, United States
Eric C. McGary
Recruiting
Uc San Diego Moores Cancer Center
La Jolla, California, United States
Lyudmila A. Bazhenova
Recruiting
City of Hope Antelope Valley
Lancaster, California, United States
Tanyanika L. Phillips
Recruiting
Loma Linda University Medical Center
Loma Linda, California, United States
Hamid R. Mirshahidi
Recruiting
Cedars-Sinai Medical Center
Los Angeles, California, United States
Karen L. Reckamp
Recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Eric C. McGary
Recruiting
Kaiser Permanente West Los Angeles
Los Angeles, California, United States
Eric C. McGary
Recruiting
Fremont - Rideout Cancer Center
Marysville, California, United States
Tianhong Li
Recruiting
Mather Veteran Affairs Medical Center
Mather, California, United States
Tianhong Li
Recruiting
Kaiser Permanente-Oakland
Oakland, California, United States
Jennifer M. Suga
Recruiting
Kaiser Permanente-Ontario
Ontario, California, United States
Eric C. McGary
Recruiting
Va Palo Alto Health Care System
Palo Alto, California, United States
Suspended
Kaiser Permanente - Panorama City
Panorama City, California, United States
Eric C. McGary
Recruiting
Eisenhower Medical Center
Rancho Mirage, California, United States
Davood Vafai
Recruiting
Kaiser Permanente-Riverside
Riverside, California, United States
Eric C. McGary
Recruiting
Kaiser Permanente-Roseville
Roseville, California, United States
Jennifer M. Suga
Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California, United States
Jennifer M. Suga
Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Tianhong Li
Recruiting
Kaiser Permanente-San Diego Zion
San Diego, California, United States
Eric C. McGary
Recruiting
Kaiser Permanente-San Francisco
San Francisco, California, United States
Jennifer M. Suga
Recruiting
Veterans Affairs Medical Center - San Francisco
San Francisco, California, United States
Sunny Wang
Recruiting

346 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cemiplimab →Dexamethasone →Docetaxel →Ramucirumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 May 2025
Primary completion: 31 Dec 2027
Completion: 31 Dec 2028
Last update posted: 5 May 2026
Registered enrollment: 378
Registry id: NCT06616584

Cross-registrations

Other registry (CTRP (Clinical Trial Reporting ProgramNCI-2024-06444

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.